NCT07197294View on ClinicalTrials.gov

Personalized Antisense Oligonucleotide for a Single Participant With MAPK8IP3 Neurodevelopmental Disorder With or Without Variable Brain Abnormalities (NEDBA)

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

February 24, 2025

Primary Completion Date

February 28, 2027

Study Completion Date

February 28, 2027

Conditions

Neurodevelopmental Disorder With or Without Variable Brain Abnormalities

Interventions

DRUG

nL-MAPK8-001

Personalized antisense oligonucleotide

Trial Locations (1)

10032

Columbia University, New York

All Listed Sponsors

collaborator

Columbia University

OTHER

lead

n-Lorem Foundation

OTHER

NCT07197294 - Personalized Antisense Oligonucleotide for a Single Participant With MAPK8IP3 Neurodevelopmental Disorder With or Without Variable Brain Abnormalities (NEDBA) | Biotech Hunter | Biotech Hunter